ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

ProMIS Neurosciences和其他2只股票在5美元以下，高管正在购买

Benzinga · 09/19 09:17

The Dow Jones index closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

WidePoint

The Trade: WidePoint Corporation (NYSE:WYY) CEO Jin Kang bought a total of 1,000 shares at an average price of $3.50. To acquire these shares, it cost around $3,499.
What's Happening: On Aug. 14, WidePoint posted a second-quarter GAAP loss of 5 cents per share.
What WidePoint Does: WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution.

ProMIS Neurosciences

The Trade: ProMIS Neurosciences, Inc. (NASDAQ:PMN) 10% owner Michael S Gordon acquired a total of 93,223 shares at an average price of $1.25. To acquire these shares, it cost around $116,880.
What's Happening: On Aug. 29, ProMIS Neurosciences filed for resale from time to time of 56.5 million common shares of the company by selling stockholders.
What ProMIS Neurosciences Does: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

Emmaus Life Sciences

The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Director Seah H. Lim acquired a total of 20,000 shares at an average price of $0.04. The insider spent around $800 to buy those shares.
What's Happening: On Sept. 10, the company said net revenues for the six months ended June 30 were $7.9 million, down from $17.5 million in the year-ago period.
What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases.

FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

The Dow Jones index closed lower by over 100 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

道琼斯指数周三下跌超过100点。当内部人购买或卖出股票时，这表明他们对公司前景的信心或担忧。对于对低价股感兴趣的投资者和交易员来说，他们可以将这视为他们整体投资或交易决策的一个因素。

Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.

以下是几个近期关于低价股的值得关注的内部交易。了解更多，请查看Benzinga内幕交易平台。

WidePoint

widepoint

The Trade: WidePoint Corporation (NYSE:WYY) CEO Jin Kang bought a total of 1,000 shares at an average price of $3.50. To acquire these shares, it cost around $3,499.
What's Happening: On Aug. 14, WidePoint posted a second-quarter GAAP loss of 5 cents per share.
What WidePoint Does: WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and Information Technology as a Service solution.

交易：WidePoint Corporation（纽交所：WYY）CEO Jin Kang以3.50美元的平均价格购买了总计1,000股。购买这些股票需要花费约3,499美元。
正在发生的事情：8月14日，WidePoint发布了第二季度按照美国通用会计准则计算的每股亏损为5美分。
WidePoint Corp是提供科技管理服务（TMaaS）的供应商，包括联邦认证的通信管理、身份管理、互动账单呈现和分析以及信息技术服务解决方案。

ProMIS Neurosciences

ProMIS神经科学

The Trade: ProMIS Neurosciences, Inc. (NASDAQ:PMN) 10% owner Michael S Gordon acquired a total of 93,223 shares at an average price of $1.25. To acquire these shares, it cost around $116,880.
What's Happening: On Aug. 29, ProMIS Neurosciences filed for resale from time to time of 56.5 million common shares of the company by selling stockholders.
What ProMIS Neurosciences Does: ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA).

交易：ProMIS Neurosciences，Inc.（纳斯达克：PMN）的10％所有人Michael S Gordon以1.25美元的平均价格收购了总计93,223股。购买这些股票需要花费约116,880美元。
动态: 8月29日，ProMIS神经科学公司通过出售股票股东，向日销售5650万普通股。
ProMIS神经科学做什么：ProMIS神经科学公司是一家临床阶段的生物技术公司，专注于生成和开发选择性靶向神经退行性疾病（如阿尔茨海默病（AD）、肌萎缩性侧索硬化（ALS）和多系统萎缩（MSA））中有毒错位蛋白的抗体治疗药物。

Emmaus Life Sciences

Emmaus生命科学

The Trade: Emmaus Life Sciences, Inc. (OTC:EMMA) Director Seah H. Lim acquired a total of 20,000 shares at an average price of $0.04. The insider spent around $800 to buy those shares.
What's Happening: On Sept. 10, the company said net revenues for the six months ended June 30 were $7.9 million, down from $17.5 million in the year-ago period.
What Emmaus Life Sciences Does: Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases.

交易：Emmaus生命科学公司（OTC:EMMA）董事Seah H. Lim以平均价格0.04美元购入总共2万股股票。这位内部人士花了约800美元买这些股票。
动态: 9月10日，该公司表示截至6月30日的六个月净收入为790万美元，低于去年同期的1750万美元。
Emmaus生命科学公司业务范围: Emmaus Life Sciences Inc是一家生物制药公司，致力于发现、开发和商业化罕见和孤儿疾病的新治疗方法和疗法。

FedEx Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

联邦快递准备启动第一季度的印刷工作；以下是华尔街最准确分析师最近的预测变化

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。更多信息